NCT04906460View on ClinicalTrials.gov

Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

June 27, 2026

Study Completion Date

April 24, 2027

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

WVE-N531

WVE-N531 is an antisense oligonucleotide (ASO)

Trial Locations (3)

Unknown

ACTIVE_NOT_RECRUITING

Istiklal Hospital/ Clinical Research Unit, Amman

ACTIVE_NOT_RECRUITING

The Specialty Hospital (TSH)/ Advanced Clinical Center, Amman

OX3 9DU

RECRUITING

Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust, Headington

All Listed Sponsors
lead

Wave Life Sciences Ltd.

INDUSTRY